• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病毒样颗粒对去唾液酸糖蛋白受体的多价靶向作用。

Multivalent Targeting of the Asialoglycoprotein Receptor by Virus-Like Particles.

机构信息

School of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Drive, Atlanta, GA, 30332, USA.

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory School of Medicine, 313 Ferst Dr NW, Atlanta, GA, 30332, USA.

出版信息

Small. 2023 Dec;19(52):e2304263. doi: 10.1002/smll.202304263. Epub 2023 Aug 30.

DOI:10.1002/smll.202304263
PMID:37649182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10840735/
Abstract

The asialoglycoprotein receptor (ASGPR) is expressed in high density on hepatocytes. Multivalent variants of galactosyl carbohydrates bind ASGPR with high affinity, enabling hepatic delivery of ligand-bound cargo. Virus-like particle (VLP) conjugates of a relatively high-affinity ligand were efficiently endocytosed by ASGPR-expressing cells in a manner strongly dependent on the nature and density of ligand display, with the best formulation using a nanomolar-, but not a picomolar-level, binder. Optimized particles were taken up by HepG2 cells with greater efficiency than competing small molecules or the natural multigalactosylated ligand, asialoorosomucoid. Upon systemic injection in mice, these VLPs were rapidly cleared to the liver and were found in association with sinusoidal endothelial cells, Kupffer cells, hepatocytes, dendritic cells, and other immune cells. Both ASGPR-targeted and nontargeted particles were distributed similarly to endothelial and Kupffer cells, but targeted particles were distributed to a greater number and fraction of hepatocytes. Thus, selective cellular trafficking in the liver is difficult to achieve: even with the most potent ASGPR targeting available, barrier cells take up much of the injected particles and hepatocytes are accessed only approximately twice as efficiently in the best case.

摘要

去唾液酸糖蛋白受体 (ASGPR) 在肝细胞上高表达。具有多价的半乳糖基碳水化合物与 ASGPR 具有高亲和力结合,使配体结合的货物能够递送到肝脏。相对高亲和力配体的病毒样颗粒 (VLP) 缀合物通过 ASGPR 表达细胞的内吞作用被有效摄取,这种内吞作用强烈依赖于配体展示的性质和密度,最佳配方使用纳摩尔级而不是皮摩尔级的结合剂。优化后的颗粒被 HepG2 细胞摄取的效率高于竞争的小分子或天然的多半乳糖基配体,即去唾液酸糖蛋白。在小鼠体内系统注射后,这些 VLP 迅速被清除到肝脏,并与窦状内皮细胞、枯否细胞、肝细胞、树突状细胞和其他免疫细胞相关联。靶向 ASGPR 的和非靶向的颗粒在分布上与内皮细胞和枯否细胞相似,但靶向的颗粒分布到更多数量和比例的肝细胞中。因此,在肝脏中实现选择性细胞转运是困难的:即使使用最有效的 ASGPR 靶向,屏障细胞也会摄取大量注射的颗粒,而在最佳情况下,只有大约两倍的肝细胞能够更有效地被摄取。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/6245a42b8f89/nihms-1929396-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/1c81cfe7d2b4/nihms-1929396-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/d1bb16e4e447/nihms-1929396-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/70cc995e6874/nihms-1929396-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/a5769a9366e2/nihms-1929396-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/6245a42b8f89/nihms-1929396-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/1c81cfe7d2b4/nihms-1929396-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/d1bb16e4e447/nihms-1929396-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/70cc995e6874/nihms-1929396-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/a5769a9366e2/nihms-1929396-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0683/10840735/6245a42b8f89/nihms-1929396-f0006.jpg

相似文献

1
Multivalent Targeting of the Asialoglycoprotein Receptor by Virus-Like Particles.病毒样颗粒对去唾液酸糖蛋白受体的多价靶向作用。
Small. 2023 Dec;19(52):e2304263. doi: 10.1002/smll.202304263. Epub 2023 Aug 30.
2
Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo.体外和体内肝细胞上脱唾液酸糖蛋白受体摄取和处理配体的大小上限的测定。
J Biol Chem. 2001 Oct 5;276(40):37577-84. doi: 10.1074/jbc.M101786200. Epub 2001 Jul 30.
3
Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.Asialoglycoprotein 受体介导的肝细胞靶向 - 策略与应用。
J Control Release. 2015 Apr 10;203:126-39. doi: 10.1016/j.jconrel.2015.02.022. Epub 2015 Feb 18.
4
The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers.去唾液酸糖蛋白受体介导肝脏对来自病毒血症携带者的天然乙型肝炎病毒颗粒的结合和摄取。
J Gen Virol. 1994 Nov;75 ( Pt 11):3021-9. doi: 10.1099/0022-1317-75-11-3021.
5
Capacity limits of asialoglycoprotein receptor-mediated liver targeting.去唾液酸糖蛋白受体介导的肝脏靶向的容量限制。
MAbs. 2017 Nov/Dec;9(8):1360-1369. doi: 10.1080/19420862.2017.1373924. Epub 2017 Sep 6.
6
Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor.通过多价展示用于去唾液酸糖蛋白受体的紧凑配体实现高效的肝脏靶向。
J Am Chem Soc. 2017 Mar 8;139(9):3528-3536. doi: 10.1021/jacs.6b12964. Epub 2017 Feb 23.
7
Physiological roles of asialoglycoprotein receptors (ASGPRs) variants and recent advances in hepatic-targeted delivery of therapeutic molecules via ASGPRs.去唾液酸糖蛋白受体(ASGPRs)变体的生理作用以及通过ASGPRs进行治疗性分子肝靶向递送的最新进展。
Protein Pept Lett. 2014;21(10):1025-30. doi: 10.2174/0929866521666140626102429.
8
Kukoamine B promotes TLR4-independent lipopolysaccharide uptake in murine hepatocytes.库可胺B促进小鼠肝细胞中不依赖Toll样受体4的脂多糖摄取。
Oncotarget. 2016 Sep 6;7(36):57498-57513. doi: 10.18632/oncotarget.11292.
9
Complement-mediated cytotoxicity and inhibition of ligand binding to hepatocytes by woodchuck hepatitis virus-induced autoantibodies to asialoglycoprotein receptor.土拨鼠肝炎病毒诱导的抗去唾液酸糖蛋白受体自身抗体介导的细胞毒性及对配体与肝细胞结合的抑制作用
Hepatology. 1998 Jun;27(6):1623-31. doi: 10.1002/hep.510270623.
10
Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages.体内通过半乳糖受体的内吞作用。配体大小决定肝细胞和/或肝巨噬细胞的摄取。
Exp Cell Res. 1986 Aug;165(2):494-506. doi: 10.1016/0014-4827(86)90602-6.

引用本文的文献

1
Emerging strategies against accelerated blood clearance phenomenon of nanocarrier drug delivery systems.针对纳米载体药物递送系统加速血液清除现象的新兴策略。
J Nanobiotechnology. 2025 Feb 25;23(1):138. doi: 10.1186/s12951-025-03209-0.
2
Understanding nanoparticle-liver interactions in nanomedicine.纳米医学中纳米颗粒与肝脏的相互作用研究
Expert Opin Drug Deliv. 2024 Jun;21(6):829-843. doi: 10.1080/17425247.2024.2375400. Epub 2024 Jul 4.

本文引用的文献

1
Why nanoparticles prefer liver macrophage cell uptake in vivo.为什么纳米颗粒在体内更倾向于被肝巨噬细胞摄取。
Adv Drug Deliv Rev. 2022 Jun;185:114238. doi: 10.1016/j.addr.2022.114238. Epub 2022 Mar 31.
2
The Scavenger Function of Liver Sinusoidal Endothelial Cells in Health and Disease.肝窦内皮细胞在健康与疾病中的清除功能
Front Physiol. 2021 Oct 11;12:757469. doi: 10.3389/fphys.2021.757469. eCollection 2021.
3
Bifunctional small molecules that mediate the degradation of extracellular proteins.介导细胞外蛋白质降解的双功能小分子。
Nat Chem Biol. 2021 Sep;17(9):947-953. doi: 10.1038/s41589-021-00851-1. Epub 2021 Aug 19.
4
Single-Point Mutations in Qβ Virus-like Particles Change Binding to Cells.Qβ 病毒样颗粒单点突变改变与细胞的结合。
Biomacromolecules. 2021 Aug 9;22(8):3332-3341. doi: 10.1021/acs.biomac.1c00443. Epub 2021 Jul 12.
5
Chemical modification of the adeno-associated virus capsid to improve gene delivery.对腺相关病毒衣壳进行化学修饰以改善基因递送。
Chem Sci. 2019 Dec 9;11(4):1122-1131. doi: 10.1039/c9sc04189c.
6
Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins.三触角N-乙酰半乳糖胺缀合物作为细胞外蛋白质降解剂的开发。
ACS Cent Sci. 2021 Mar 24;7(3):499-506. doi: 10.1021/acscentsci.1c00146. Epub 2021 Mar 4.
7
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation.靶向结合去唾液酸糖蛋白受体的 LYTACs 用于蛋白质靶向降解。
Nat Chem Biol. 2021 Sep;17(9):937-946. doi: 10.1038/s41589-021-00770-1. Epub 2021 Mar 25.
8
Prominent Receptors of Liver Sinusoidal Endothelial Cells in Liver Homeostasis and Disease.肝窦内皮细胞在肝脏稳态与疾病中的重要受体
Front Physiol. 2020 Jul 21;11:873. doi: 10.3389/fphys.2020.00873. eCollection 2020.
9
Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses.聚糖修饰的病毒样颗粒引发1型辅助性T细胞样免疫反应。
ACS Nano. 2021 Jan 26;15(1):309-321. doi: 10.1021/acsnano.0c03023. Epub 2020 Aug 17.
10
The dose threshold for nanoparticle tumour delivery.纳米颗粒肿瘤递呈的剂量阈值。
Nat Mater. 2020 Dec;19(12):1362-1371. doi: 10.1038/s41563-020-0755-z. Epub 2020 Aug 10.